Skip navigation
Speakers

Using Genome-Editing to Reduce Drug Development Timelines, Improve Clinical Outcomes and Optimize Manufacturing Processes

December 13, 2017
  • Cambridge, MA

Martin Akerman
Co-Founder & CTO
Envisagenics Inc.

Mark A. Behlke, MD, PhD
Chief Scientific Officer
Integrated DNA Technologies, Inc.

Amrit Chaudhuri
CEO & Founder
Mass Innovation Labs

Niven Narain
Co-Founder, President & CEO
Berg Health

Marco Ruella, MD
Clinical Instructor, Associate Director,
Dr. June’s Laboratory, Center for Cellular Immunotherapies
University of Pennsylvania

Jonathan Schmid-Burgk, PhD
Zhang Lab Postdoctoral Fellow
Broad Institute of MIT and Harvard

Michael G. Smith, PhD
Senior Sequencing Specialist
Illumina

Lance Weed
Vice President, Operations
uniQure

Martin Akerman
Co-Founder & CTO
Envisagenics Inc.

Mark A. Behlke, MD, PhD
Chief Scientific Officer
Integrated DNA Technologies, Inc.

Amrit Chaudhuri
CEO & Founder
Mass Innovation Labs

Niven Narain
Co-Founder, President & CEO
Berg Health

Marco Ruella, MD
Clinical Instructor, Associate Director,
Dr. June’s Laboratory, Center for Cellular Immunotherapies
University of Pennsylvania

Jonathan Schmid-Burgk, PhD
Zhang Lab Postdoctoral Fellow
Broad Institute of MIT and Harvard

Michael G. Smith, PhD
Senior Sequencing Specialist
Illumina

Lance Weed
Vice President, Operations
uniQure